CRISPR-Armed Phages Clear First Human Safety Bar

The Copenhagen-based biotech has spent the past several years engineering bacteriophages to precisely target Escherichia coli in the gastrointestinal tract, working to prevent bloodstream infections in patients with haematological malignancies undergoing stem-cell transplantation. The newly published first-in-human trial now provides the safety and feasibility signal required to move the programme into patient studies.

For Eric van der Helm, VP Business Development at SNIPR, the significance goes beyond the dataset itself. »This study delivered a very clear message on feasibility and safety. In a randomised, controlled first-in-human trial, we showed that orally administered engineered phages are safe and well-tolerated, including at higher doses. This has not been shown before for an orally dosed CRISPR–Cas-armed phage therapeutic, and it sets an important benchmark for the field.«

SNIPR arms phages with programmable killing

The scientific groundwork for SNIPR001 was published in Nature Biotechnology in 2024, describing a development process that builds on classic phage therapy, layering programmable killing on top. After screening 162 wild-type lytic phages for breadth and complementarity, SNIPR selected candidates that bind different bacterial surface receptors, reducing the chance that E. coli could evade the cocktail through a single mutation.

Efficacy was not the primary endpoint. Nevertheless, the highest-dose group showed a 78% reduction in E. coli levels versus placebo at day 14, though this did not reach statistical significance (see Figure 2). Van der Helm is explicit about how the company reads that signal. »It's important to frame the result in the context of the study design: this trial was powered for safety, not for detecting statistically significant reductions in E. coli. So we did not anticipate a conclusive efficacy readout. That said, the fact that we saw a dose-dependent trend is meaningful to us; it suggests E. coli target engagement and supports the decision to move forward into a phase 1b/2a trial in patients.«

SNIPR001 is built around a clearly defined, high-risk group: patients with haematological cancer undergoing stem-cell transplantation, where neutropenia and damage to the gut lining increase the risk of bloodstream infections, and fluoroquinolone resistance is common. The ongoing phase 1b/2a trial, now more than halfway enrolled across eight US cancer centres, is evaluating SNIPR001 in precisely this population.

»The biology is different,« says Christian Grøndahl, Founder and CEO at SNIPR. »The microbiome of the intended patient population can differ substantially from that of healthy volunteers, and E. coli can be present at much higher abundance. In that context, we expect SNIPR001 to have more dynamic range to demonstrate activity.« A dysbiotic, high-burden microbiome may yield a clearer therapeutic window – and a more compelling efficacy signal – than a stable, healthy gut.

Platform strategy targets a structurally broken market

CRISPR-based antimicrobials remain an emerging category. SNIPR001 sits between traditional antibiotics and broad microbiome therapeutics: a genetically programmed, pathogen-specific antibacterial with a defined molecular mechanism. The wider market context is well established – in 2019, antibiotic-resistant bacteria were estimated to have directly caused 1.27 million deaths globally, with E. coli the single largest contributor, and few novel antibiotic classes are advancing through late-stage development.

Grøndahl frames the positioning in systemic terms. »Antibiotic resistance continues to rise globally, and antibiotics remain a mainstay of modern medicine – without effective antibiotics, many routine hospital procedures become far more difficult if not impossible. We therefore believe innovation in antimicrobials is essential to protect both current and future healthcare. In that landscape, we position SNIPR001 primarily as a means to prevent infections in the first place, particularly in high-risk settings. At the same time, we have encouraging data supporting the potential for treating active infection. Strategically, it's also important that SNIPR001 is built on a platform: we've applied the same approach used to generate SNIPR001 to create CRISPR-based medicines against other high-priority threats, including Klebsiella and Pseudomonas.«